AstraZeneca’s Forxiga approved in EU for chronic heart failure
pharmafile | February 7, 2023 | News story | Medical Communications |
AstraZeneca has announced that its drug, Forxiga, has been approved in the EU for the treatment of symptomatic chronic heart failure. This follows an approval from the EMA’s Committee for Medicinal Products for Human Use in December.
The drug is already approved in the EU for the treatment of type 2 diabetes as well as chronic kidney disease. It has also received regulatory approvals in Britain, Japan and Turkey, as well as the US and now the EU.
The company commented that the approval marks the “first and only heart failure therapy with proven mortality benefit across the full ejection fraction range.” They also quoted a 2008 study endorsed by the European Society of Intensive Care Medicine, saying that heart failure impacts around 15 million people in Europe. It is clear that a new heart failure treatment option is a hugely positive step forward for healthcare practitioners, patients and their families.
Mene Pangalos, executive vice president at AstraZeneca’s BioPharmaceuticals research and development unit, commented: “This broader indication for Forxiga for the treatment of symptomatic chronic heart failure across the full ejection range will help more patients to benefit from this well-tolerated and guideline-directed treatment. We are redefining treatment of cardiorenal diseases with Forxiga’s demonstration of life-saving benefits, underscoring AstraZeneca’s commitment to provide innovative solutions that can help address the complexities of heart failure across the spectrum of the disease.”